Quick Answer
Theriva Biologics, Inc. reported Operating Income of -$24.05 million for fiscal year 2025.
Theriva Biologics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$24.05M | +8.7% |
| 2024 | -$26.35M | -22.9% |
| 2023 | -$21.43M | +0.7% |
| 2022 | -$21.58M | -51.2% |
| 2021 | -$14.27M | -40.5% |
| 2020 | -$10.16M | +35.1% |
| 2019 | -$15.66M | +10.9% |
| 2018 | -$17.57M | +33.1% |
| 2017 | -$26.25M | +33.1% |
| 2016 | -$39.25M | +4.2% |
| 2015 | -$40.98M | -99.9% |
| 2014 | -$20.50M | -66.2% |
| 2013 | -$12.34M | +28.7% |
| 2012 | -$17.30M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$4.44M | +43.7% | +66.2% |
| June 30, 2025 | -$13.13M | -54.7% | -197.3% |
| March 31, 2025 | -$4.42M | +18.1% | +44.0% |
| September 30, 2024 | -$7.89M | -87.0% | +7.1% |
| June 30, 2024 | -$8.49M | -45.8% | -57.4% |
| March 31, 2024 | -$5.39M | -4.1% | -27.8% |
| September 30, 2023 | -$4.22M | +15.4% | +27.5% |
| June 30, 2023 | -$5.82M | -15.8% | -12.4% |
- Theriva Biologics, Inc. showed an increase of +8.7% in Operating Income compared to the prior fiscal year.
- Over the 2012–2025 period, Theriva Biologics, Inc.’s operating income has declined by 39.0% (from -$17.30 million to -$24.05 million).
- The most recent figure is from Theriva Biologics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: